Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Alisha DeTroye"'
Autor:
Chris Gillette, Gayle B. Bodner, Caroline Grey Bell Sisson, Nathan Bates, Alisha DeTroye, Sobia S. Hussaini, Sonia Crandall
Publikováno v:
Journal of Physician Assistant Education. 34:147-151
Autor:
Alisha, DeTroye, Kayla, Gabbett, Cheryl, Yi, Melanie, Judice, Victor, Luu, Brittany, Nelson, Tanya, Gregory
Publikováno v:
JAAPA. 35:48-52
The field of cancer genetic testing has made great advances in correctly identifying patients at risk for hereditary cancer syndromes. These tests, used during a genetic consultation, promote earlier detection of cancer and potentially increase survi
Autor:
John Dorsey, Ryan Mott, Christopher Lack, Nicholas Britt, Shakti Ramkissoon, Bonny Morris, Annette Carter, Alisha Detroye, Michael Chan, Stephen Tatter, Glenn Lesser
Publikováno v:
Oncology Letters. 24
Autor:
Naqeeb M Faroqui, Robin Petro, Roy E. Strowd, Annette Carter, Kristin Strickland Houston, Glenn J. Lesser, Alisha DeTroye, Marin Abousaud, Shakti H. Ramkissoon, Fang-Chi Hsu, Madan M. Kwatra
Publikováno v:
Journal of Cancer Science and Clinical Therapeutics.
Background: EGFR alterations are commonly observed in malignant gliomas (MG). Osimertinib, an irreversible EGFR-tyrosine kinase inhibitor, effectively penetrates the blood brain barrier and achieves therapeutic concentrations in brain tissue. Materia
Autor:
Danielle Eganhouse, Margaret Christner, Emily Sunkin, Brittany Manning, Alisha DeTroye, Tanya Gregory
Publikováno v:
Journal of the American Academy of Physician Assistants. 31:21-25
Mortality from colorectal cancer has been declining over the past 20 years due to improvements in screening and treatment. Physical activity improves patient quality of life, slows functional decline, and reduces all-cause mortality. Although some pa
Autor:
Roy E. Strowd, Glenn J. Lesser, Annette Carter, Alisha DeTroye, Naqeeb M Faroqui, Shakti H. Ramkissoon, Fang-Chi Hsu, Kristin Strickland Houston, Marin Abousaud, Madan M. Kwatra
Publikováno v:
Neuro Oncol
EGFR alterations are commonly observed in malignant gliomas (MG), especially glioblastomas, making this pathway an appealing therapeutic target. Unlike other EGFR tyrosine kinase inhibitors (TKIs), osimertinib (osi), a third-generation, irreversible
Autor:
Mollie Rose Canzona, Kathryn Weaver, Kristin Strickland Houston, Angelica Hutchinson, Annette Carter, Fang-Chi Hsu, Michael D. Chan, Adrian W. Laxton, Glenn J. Lesser, Stephen Tatter, Alisha DeTroye, Alexandria Marshall, Roy E. Strowd, Christina K. Cramer
Publikováno v:
Neuro Oncol
BACKGROUND Social determinants of health (SDH) are modifiable factors that contribute to health outcomes. Despite studies linking SDHs with cervical, ovarian, and prostate cancer outcomes, few studies have explored SDHs in glioma patients. We conduct
Autor:
Glenn J. Lesser, Michele Harmon, Alisha DeTroye, Annette Carter, Janet A. Tooze, Robert Morrell
Publikováno v:
Journal of Oncology Practice. 9:e268-e271
Patient compliance with routine monitoring for self-administered chemotherapy is problematic. We sought to assess monitoring lapses and incidents of myelosuppression in patients undergoing self-administered chemotherapy for glioblastoma, as well as t
Autor:
Thomas L. Ellis, Annette J. Johnson, Ryan T. Mott, Glenn J. Lesser, Alisha DeTroye, Michael D. Chan, Kevin P. McMullen, Stephen B. Tatter, Jaclyn J. Renfrow
Publikováno v:
Journal of Neuro-Oncology. 107:659-663
Novel therapeutic options for patients with recurrent primary central nervous system lymphoma (RPCNSL) are needed. Bendamustine, a bifunctional purine analog/alkylating agent, is approved for use in patients with progressive systemic indolent non-Hod
Autor:
Glenn J. Lesser, Michele Harmon, Alisha DeTroye, Robert Morrell, Janet A. Tooze, Annette Carter
Publikováno v:
Journal of Clinical Oncology. 30:296-296
296 Background: Protracted outpatient oral chemotherapy regimens have created new challenges for monitoring patients for toxicity. Unlike IV chemotherapy which guarantees clinician access to the patient before proceeding with therapy, oral agents can